191 related articles for article (PubMed ID: 19691126)
41. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
42. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
[TBL] [Abstract][Full Text] [Related]
43. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
Fox SH; Chuang R; Brotchie JM
Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
[TBL] [Abstract][Full Text] [Related]
44. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic strategies to prevent motor complications in Parkinson's disease.
Kieburtz K
J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
[TBL] [Abstract][Full Text] [Related]
46. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
47. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
Hauser RA; McDermott MP; Messing S
Arch Neurol; 2006 Dec; 63(12):1756-60. PubMed ID: 17172616
[TBL] [Abstract][Full Text] [Related]
48. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
49. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
McColl CD; Reardon KA; Shiff M; Kempster PA
Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
51. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
52. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
53. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
Fox S; Silverdale M; Kellett M; Davies R; Steiger M; Fletcher N; Crossman A; Brotchie J
Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
[TBL] [Abstract][Full Text] [Related]
54. Risk and course of motor complications in a population-based incident Parkinson's disease cohort.
Bjornestad A; Forsaa EB; Pedersen KF; Tysnes OB; Larsen JP; Alves G
Parkinsonism Relat Disord; 2016 Jan; 22():48-53. PubMed ID: 26585090
[TBL] [Abstract][Full Text] [Related]
55. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia.
Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A
Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240
[TBL] [Abstract][Full Text] [Related]
56. [Secondary effects of chronic treatment with levodopa in Parkinson disease].
Baltag D; Ignat B; Manole OZ
Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):131-5. PubMed ID: 14755983
[TBL] [Abstract][Full Text] [Related]
57. Quantitative motor assessment of dyskinesias in Parkinson's disease.
Schaeffer E; Maetzler W; Liepelt-Scarfone I; Sass C; Reilmann R; Berg D
J Neural Transm (Vienna); 2015 Sep; 122(9):1271-8. PubMed ID: 25712401
[TBL] [Abstract][Full Text] [Related]
58. rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
Koch G
Restor Neurol Neurosci; 2010; 28(4):561-8. PubMed ID: 20714078
[TBL] [Abstract][Full Text] [Related]
59. The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications.
Kostić VS; Marinković J; Svetel M; Stefanova E; Przedborski S
Eur J Neurol; 2002 Jan; 9(1):9-14. PubMed ID: 11784369
[TBL] [Abstract][Full Text] [Related]
60. Does the Side Onset of Parkinson's Disease Influence the Time to Develop Levodopa-Induced Dyskinesia?
Chung SJ; Yoo HS; Lee HS; Lee PH; Sohn YH
J Parkinsons Dis; 2019; 9(1):241-247. PubMed ID: 30741690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
